## ACA PREVENTION COPAY WAIVER COPAY WAIVER REQUEST

PRESCRIBER FAX FORM

Only the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.

The following documentation is <u>REQUIRED</u>. Incomplete forms will be returned for additional information. For formulary information please visit <u>www.myprime.com</u>. Start saving time today by filling out this form electronically. Visit <u>covermymeds.com</u> to begin using this free service.

this free service.		-		•			_	
What is the priority level of this req	uest?							
☐ Standard review	_ nrescriber certifies the	at waiting t	for a stand	ard review c	ould sa	riously harm the patient's life,		
health or ability to regain max		at waiting	ioi a stariu					
DATIENT AND INCUDANCE INCODE	AATION D.	-460	(:6			Date:		
PATIENT AND INSURANCE INFORM Patient Name (First):	Last:	ate of Ser	vice (it ain	fers from To		(mm/dd/yyyy):		
rauent Name (First).	Last.			IVI.	БОВ	(IIIII/dd/yyyy).		
Patient Address: City, State, Zip:				Pati	tient Telephone:			
Marie Las ID News Las		Group Number:						
Member ID Number:		'	Group Numi	per:				
PRESCRIBER/CLINIC INFORMATIO	N							
Prescriber Name:	Prescriber NPI#:	scriber NPI#: Specialty:		Contact Name:				
Clinic Name:		Clinic Address:						
Cirile Ivairie.		Cililic Address.						
City, State, Zip:		Phone #:		Secure		re Fax #:		
PLEASE ATTACH ANY ADDITIONAl Patient's Diagnosis - ICD code plus		TSHOUL	D BE CON	SIDERED W	VITH TI	HIS REQUEST		
Fatient's Diagnosis - 100 code plus (	description.							
Medication Requested:			Strength:					
Dosing Schedule:				Quantity per Month:				
Dosing Scriedule.				Quantity per Month.				
For all requests:								
1. Is the patient currently treated with the requested agent? ☐ Yes ☐ No								
2. Is the requested agent medically necessary? ☐ Yes ☐ No								
For aspirin requests:								
3. Is the patient pregnant, at high r	isk of preeclampsia, an	d using th	e requeste	d agent afte	r 12 we	eks		
of gestation?						Yes N	lo	
For bowel prep requests:								
4. Will the requested agent be use	d for the preparation of	colorectal	cancer sci	reening using	g fecal	occult		
blood testing, sigmoidoscopy, or colonoscopy?								
For breast cancer prevention requ	ests:							
5. Is the requested breast cancer primary prevention agent medically necessary?								
6. Is the agent requested for the primary prevention of breast cancer?								
For folic acid requests:								
7. Does the requested folic acid supplement contain 0.4-0.8 mg of folic acid?								
8. Is the requested folic acid supplement to be used in support of pregnancy?								
For HIV infection: pre-exposure pr								
9. Is the requested agent being used for PrEP?								
10. Does the patient have increased risk for HIV infection?								
11. Has the patient recently tested negative for HIV?								
For infant eye ointment requests:								
12. Is the requested agent requeste	d for the prevention of o	gonococca	al ophthalm	ia neonatoru	um?	Yes N	lo	
Please continue to the next page.		-	·					

6324 ILMTNMOKTX COWA 0524 Page 1 of 2

For iron supplement requests:  13. Is the patient at increased risk for iron deficiency anemia?								
For statin requests:								
	s 🗌 No							
14. Is the requested statin for use in the primary prevention of cardiovascular disease (CVD)?	s 🗌 No							
14. Is the requested statin for use in the primary prevention of cardiovascular disease (CVD)?								
15. Does the patient have at least one of the following risk factors: 1) dyslipidemia, 2) diabetes, 3) hypertension,								
or 4) smoking?	S No							
16. Does the patient have a calculated 10-year risk of a cardiovascular event of 10% or greater per the American								
College of Cardiology and American Heart Association's Atherosclerotic Cardiovascular Disease (ASCVD)								
calculator?	s 🗌 No							
For tobacco cessation:								
17. Is the patient a non-pregnant adult?	s □ No							
For vaccines:								
18. Will the requested vaccine be used per the recommendations of the Advisory Committee on Immunization								
Practices/CDC?	s 🗌 No							
	CONFIDENTIALITY NOTICE: This communication is							
Prime Therapeutics LLC Clinical Review Department intended only for the use of the individual entity to								
	it is addressed, and may contain information that is							
Eagan, MN 55121 privileged or confidential. If the reader of this mes	•							
	not the intended recipient, you are hereby notified that							
Phone: Fax: 877.243.6930 any dissemination, distribution or copying of this BCBSIL: 800.285.9426	ani mad							
BCRSMT 888 723 7443	communication is strictly prohibited. If you have received this communication in error, please return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.							
BCBSNM: 800.544.1378								